Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
1.1 To determine the recommended phase II dose for gemcitabine in combination with a fixed
dose of docetaxel and bevacizumab.
1.2 To determine the efficacy of the combination of gemcitabine, docetaxel, and bevacizumab
in patients with soft tissue sarcoma 1.3 To determine the toxicity profile of the combination
of gemcitabine, docetaxel, and bevacizumab in patients with soft tissue sarcoma